DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features

ABSTRACT Chromosomal abnormalities are detected in 20–30% of patients with chronic myelomonocytic leukemia (CMML) and correlate with prognosis. On the mutation level, disruptive alterations are particularly frequent in chromatin regulatory genes. However, little is known about the consequential alterations in the epigenetic marking of the genome. Here, we report the analysis of genomic DNA methylation patterns of 64 CMML patients and 10 healthy controls, using a DNA methylation microarray focused on promoter regions. Differential methylation analysis between patients and controls allowed us to identify abnormalities in DNA methylation, including hypermethylation of specific genes and large genome regions with aberrant DNA methylation. Unsupervised hierarchical cluster analysis identified two main clusters that associated with the clinical, biological, and genetic features of patients. Group 1 was enriched in patients with adverse clinical and biological characteristics and poorer overall and progression-free survival. In addition, significant differences in DNA methylation were observed between patients with low risk and intermediate/high risk karyotypes and between TET2 mutant and wild type patients. Taken together, our results demonstrate that altered DNA methylation patterns reflect the CMML disease state and allow to identify patient groups with distinct clinical features.

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  J. Yun,et al.  HBx‐mediated decrease of AIM2 contributes to hepatocellular carcinoma metastasis , 2017, Molecular oncology.

[3]  Jianzhong Jiang,et al.  Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer , 2017, Oncotarget.

[4]  O. Slabý,et al.  Aberrant methylation of tumour suppressor genes WT1, GATA5 and PAX5 in hepatocellular carcinoma , 2016, Clinical chemistry and laboratory medicine.

[5]  M. Cazzola,et al.  Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. , 2016, Blood.

[6]  F. Solé,et al.  Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features , 2016, Oncotarget.

[7]  Anne-Kathrin Garz,et al.  A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers , 2016, Clinical Epigenetics.

[8]  F. Solé,et al.  Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases , 2016, American journal of hematology.

[9]  H. Li,et al.  Pan-cancer methylation and expression profiling of adenocarcinomas revealed epigenetic silencing in the WNT signaling pathway. , 2016, Neoplasma.

[10]  L. Reggiani Bonetti,et al.  Molecular Features and Methylation Status in Early Onset (≤40 Years) Colorectal Cancer: A Population Based, Case-Control Study , 2015, Gastroenterology research and practice.

[11]  J. Issa,et al.  TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia. , 2015, Cancer research.

[12]  E. Estey,et al.  Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia , 2015, Epigenetics.

[13]  Omar Abdel-Wahab,et al.  Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. , 2015, The Journal of clinical investigation.

[14]  Rodney J Scott,et al.  Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value , 2015, Nature Communications.

[15]  R. Fulton,et al.  Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells , 2015, Leukemia.

[16]  C. Weng,et al.  Global methylation silencing of clustered proto-cadherin genes in cervical cancer: serving as diagnostic markers comparable to HPV , 2014, Cancer medicine.

[17]  E. Solary,et al.  Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic‐French Consortium Study , 2014, American journal of hematology.

[18]  Thomas Lengauer,et al.  Comprehensive Analysis of DNA Methylation Data with RnBeads , 2014, Nature Methods.

[19]  X. Jia,et al.  CpG island methylator phenotype of myelodysplastic syndrome identified through genome‐wide profiling of DNA methylation and gene expression , 2014, British journal of haematology.

[20]  T. Brümmendorf,et al.  Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia , 2013, Leukemia.

[21]  Zhanyu Ma,et al.  A variational Bayes beta Mixture Model for Feature Selection in DNA methylation Studies , 2013, J. Bioinform. Comput. Biol..

[22]  D. Birnbaum,et al.  Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Arenillas,et al.  Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. , 2013, Blood.

[24]  J. Hernández-Rivas,et al.  Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes , 2013, Leukemia.

[25]  E. González-Barca,et al.  Epigenetic profile in chronic lymphocytic leukemia using methylation-specific multiplex ligation-dependent probe amplification. , 2012, Epigenomics.

[26]  J. Cigudosa,et al.  TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic Leukemia , 2012, PloS one.

[27]  J. Issa,et al.  Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia , 2012, Epigenetics.

[28]  A. Vekhoff,et al.  Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. , 2011, Blood.

[29]  M. Esteller,et al.  Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome , 2011, Epigenetics.

[30]  Kai-ping Yan,et al.  Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. , 2011, The Journal of clinical investigation.

[31]  J. Cigudosa,et al.  Cytogenetic risk stratification in chronic myelomonocytic leukemia , 2011, Haematologica.

[32]  L. Aravind,et al.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.

[33]  J. Astermark,et al.  Maintenance treatment with azacytidine for patients with high‐risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy , 2010, British journal of haematology.

[34]  U. Lehmann,et al.  Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes * , 2010, European journal of haematology.

[35]  J. Issa.  Epigenetic changes in the myelodysplastic syndrome. , 2010, Hematology/oncology clinics of North America.

[36]  Mats G Gustafsson,et al.  DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. , 2010, Blood.

[37]  D. Berry,et al.  DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Nelson,et al.  Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. , 2010, Blood.

[39]  Fabien Campagne,et al.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.

[40]  D. Birnbaum,et al.  TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia , 2009, Haematologica.

[41]  Lucy Skrabanek,et al.  MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. , 2009, Blood.

[42]  Daniel Birnbaum,et al.  Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.

[43]  C. O'keefe,et al.  Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. , 2009, Blood.

[44]  Jun Yu,et al.  Promoter methylation of the Wnt/β‐catenin signaling antagonist Dkk‐3 is associated with poor survival in gastric cancer , 2008, Cancer.

[45]  L. Shaffer,et al.  ISCN 2009 - An International System for Human Cytogenetic Nomenclature , 2009 .

[46]  Taylor Jensen,et al.  Agglomerative epigenetic aberrations are a common event in human breast cancer. , 2008, Cancer research.

[47]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[48]  Robert Brown,et al.  Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis , 2007, Clinical Cancer Research.

[49]  J. Boultwood,et al.  Gene silencing by DNA methylation in haematological malignancies , 2007, British journal of haematology.

[50]  M. Minden,et al.  A tumor suppressor and oncogene: the WT1 story , 2007, Leukemia.

[51]  W. Nelson,et al.  Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. , 2006, Genes & development.

[52]  P. Guldberg,et al.  Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patients , 2006, European journal of haematology.

[53]  J. Herman,et al.  The fundamental role of epigenetics in hematopoietic malignancies. , 2006, Blood reviews.

[54]  U. Lehmann,et al.  Hypermethylation of the suppressor of cytokine signalling‐1 (SOCS‐1) in myelodysplastic syndrome , 2005, British journal of haematology.

[55]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[56]  U. Lehmann,et al.  Role of epigenetic changes in hematological malignancies , 2004, Annals of Hematology.

[57]  A. Ganser,et al.  Aberrant methylation and impaired expression of the p15INK4b cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML) , 2003, Leukemia.

[58]  T. Maniatis,et al.  A Striking Organization of a Large Family of Human Neural Cadherin-like Cell Adhesion Genes , 1999, Cell.

[59]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[60]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .